Biohaven Corp - BHVN Forward Price-to-Revenue Multiple
Biohaven Ltd. is implementing robotic laboratories to accelerate the screening of neuroprotectors. The projected P/S value illustrates the business valuation trend, where the 1.40 level represents the current figure. AI optimizes the development of migraine medications under mandatory expert supervision. High supply profitability is maintained through production diversification and strict logistics audits.
Biohaven Corp - analytical breakdowns and key metrics (BHVN)
- market price and analyst price targets:
- issuer market value details:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital Biohaven Ltd.|BHVN - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Biohaven Ltd.|BHVN - Company Total Debt Obligations|Debts to Book Capitalization Biohaven Corp|BHVN - Company Long-Term Debt|Company Short-Term Debts Biohaven|Quick Liquidity Indicator biohavenpharma.com
- business earnings and investment ratios data:
BHVN - Company Net Income|Expected Profit Biohaven Ltd.|BHVN - Price to Earnings Multiple|Future Price to Earnings Biohaven Pharmaceutical|BHVN - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Biohaven Corp|BHVN - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Biohaven|BHVN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months biohavenpharma.com|BHVN - Earnings per share increase in current year|Net earnings per share growth forecast for next year Biohaven Ltd.
- sales revenue and business income indicators:
Comprehensive company analysis:Biohaven BHVN
Biohaven Ltd. focuses on developing innovative drugs for the treatment of severe CNS pathologies. The potential of new molecules is integrated into a calculation model where market capitalization is compared against projected future sales volumes. This metric determines the degree of market expectations for revenue from the commercialization of developments relative to the current business value. The dynamics of the forward price-to-sales ratio allow for the timely identification of asset overvaluation or the undervaluation of a promising portfolio.
Who Biohaven Ltd. competes with
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX: Market Cap to Projected Revenue|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Corp)|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|XENE (xenon-pharma.com) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple VKTX|SUPN (Supernus Pharmaceuticals, Inc.) - Price to Expected Revenue Ratio|Forward P/S Multiple CPRX|Denali Corp - Market Cap to Projected Revenue|Harmony Biosciences - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio amylyx.com (AMLX)|Trevi Therapeutics, Inc. - Forward P/S Multiple|PRAX: Price-to-Projected Revenue Ratio|AVXL: Forward P/S Multiple|CeriBell EEG - Forward Price to Sales|Forward Price-to-Revenue Multiple PRTA|Price-to-Projected Revenue Ratio ALEC|Price-to-Projected Revenue Ratio Annexon (ANNX)|omeros.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Neurogene Corp NGNE|ACIU: Market Cap to Projected Revenue|Voyager Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio neumoratx.com|SCLX (Scilex) - Forward Price-to-Revenue Multiple|Tevogen Bio Holdings Inc. (TVGN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Alpha Cognition Inc|CGTX: Forward Price to Sales|Price-to-Projected Revenue Ratio Inhibikase Therapeutics (IKT)|SAVA - Market Cap to Future Revenue Ratio|Forward P/S Multiple ASRT (Assertio)|Coya Therapeutics Inc - Price-to-Projected Revenue Ratio|VistaGen Therapeutics Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Ovid Therapeutics Inc. OVID|Acumen Pharmaceuticals (ABOS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio cervomed.com (CRVO)|ATHE (Alterity Therapeutics Ltd.) - Forward P/S Multiple|CLNN: Forward Price to Sales|Forward P/S Multiple PEPG|Forward P/S Multiple Jupiter Neurosciences, Inc. (JUNS)|Relmada Therapeutics - Forward Price-to-Revenue Multiple|annovisbio.com - Price-to-Projected Revenue Ratio|Grace Tx - Forward P/S Multiple|Market Cap to Future Revenue Ratio Firefly Neuroscience, Inc.|anewmeds.com (KLTO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue NRSN|Forward Price-to-Revenue Multiple RVPH|MTVA: Forward Price to Sales|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|Price-to-Projected Revenue Ratio HSDT (heliusmedical.com)|Passage Bio - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NEUP (Neuphoria Therapeutics, Inc.)|Minerva Neurosciences - Forward P/S Multiple|ATHA (athira.com) - Market Cap to Projected Revenue|ADXN (Addex Therapeutics Ltd) - Forward Price-to-Revenue Multiple|ALZN - Market Cap to Expected Sales Ratio|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio PTIX|Forward P/S Multiple KTTA|CRGT (cortigent.com) - Forward Price to Sales|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Brainstorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|CARA - Price-to-Projected Revenue Ratio|CHRO (Chromocell) - Market Cap to Projected Revenue|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ITCI|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Marinus Pharmaceuticals Inc MRNS|Forward Price-to-Revenue Multiple NKGN (NKGen)|Forward P/S Multiple NeuroBo Pharma (NRBO)|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|Forward Price to Sales SNPX|TRVN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vigil Neuroscience|WENA: Forward P/S Multiple|CERE (Cerevel Corp) - Price-to-Projected Revenue Ratio
